Spinal Muscular Atrophy Patients Treated with Onasemnogene Abeparvovec through a Managed Access Program: A Case Series

被引：0
|
作者：
Schultz, M.
Richardson, R.
Patterson, K.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Neuromuscular Disorders; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
197
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [31] Outcomes in patients with spinal muscular atrophy and four or more SMN2 copies treated with onasemnogene abeparvovec: Findings from RESTORE
    Finkel, R.
    Benguerba, K.
    Reid, A.
    Raju, D.
    Faulkner, E.
    LaMarca, N.
    Servais, L.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S59 - S59
  • [32] Real-world data on the effectiveness and safety of onasemnogene abeparvovec in spinal muscular atrophy
    Weiss, C.
    Becker, L.
    Garbade, S.
    Johannsen, J.
    Ziegler, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [33] Interim results from the RESPOND study evaluating nusinersen in children with spinal muscular atrophy previously treated with onasemnogene abeparvovec
    Parsons, J.
    Kuntz, N.
    Brandsema, J.
    Proud, C.
    Finkel, R.
    Swoboda, K.
    Masson, R.
    Foster, R.
    Liu, Y.
    Makepeace, C.
    Singhi, S.
    Paradis, A.
    Berger, Z.
    Rane, S.
    Somera-Molina, K.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S87 - S87
  • [34] Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec
    Tizzano, Eduardo F.
    Quijano-Roy, Susana
    Servais, Laurent
    Parsons, A.
    Parsons, Julie A.
    Aharoni, Sharon
    Lakhotia, Arpita
    Finkel, Richard S.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2024, 53 : 18 - 24
  • [35] Onasemnogene Abeparvovec for Presymptomatic Infants with Spinal Muscular Atrophy and Two Copies of SMN2
    Strauss, Kevin
    Muntoni, Francesco
    Farrar, Michelle
    Saito, Kayoko
    Mendell, Jerry
    Servals, Laurent
    McMillan, Hugh
    Finkel, Richard
    Swoboda, Kathryn
    Kwon, Jennifer
    Zaidman, Craig
    Chiriboga, Claudia
    Iannaccone, Susan
    Krueger, Jena
    Parsons, Julie
    Shieh, Perry
    Kavanagh, Sarah
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    McGill, Bryan
    Macek, Thomas
    NEUROLOGY, 2022, 98 (18)
  • [36] Outcomes in Patients with Spinal Muscular Atrophy and Four or More SMN2 Copies Treated with Onasemnogene Abeparvovec: Findings from RESTORE
    Finkel, Richard
    Benguerba, Kamal
    Gehani, Manish
    Raju, Dheeraj
    Faulkner, Eric
    LaMarca, Nicole
    Servais, Laurent
    NEUROLOGY, 2023, 100 (17)
  • [37] Early Clinical Experience with Onasemnogene Abeparvovec in Spinal Muscular Atrophy (SMA) Type 2 Patients at a Single Center
    Matesanz, Susan
    Kichula, Elizabeth
    NEUROLOGY, 2020, 94 (15)
  • [38] Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment
    McGrattan, Katlyn E.
    Shell, Richard D.
    Hurst-Davis, Rebecca
    Young, Sally Dunaway
    O'Brien, Eamonn
    Lavrov, Arseniy
    Wallach, Shiri
    LaMarca, Nicole
    Reyna, Sandra P.
    Darras, Basil T.
    JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (04) : 531 - 540
  • [39] Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands
    van der Schans, Simon
    Velikanova, Rimma
    Weidlich, Diana
    Howells, Ruth
    Patel, Anish
    Bischof, Matthias
    Postma, Maarten J.
    Boersma, Cornelis
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2025,
  • [40] Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
    Pascual-Morena, Carlos
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Rodriguez-Gutierrez, Eva
    Martinez-Vizcaino, Vicente
    HUMAN GENE THERAPY, 2023, 34 (3-4) : 129 - 138
12345